These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34577175)

  • 1. Recent Advances in the Synthesis and Biomedical Applications of Heterocyclic NO-Donors.
    Fershtat LL; Zhilin ES
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs.
    Fershtat LL; Makhova NN
    ChemMedChem; 2017 May; 12(9):622-638. PubMed ID: 28371340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiaggregant effects of (1,2,5-oxadiazolyl)azasydnone ring assemblies as novel antiplatelet agents.
    Zhilin ES; Ustyuzhanina NE; Fershtat LL; Nifantiev NE; Makhova NN
    Chem Biol Drug Des; 2022 Dec; 100(6):1017-1024. PubMed ID: 34233091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterocyclic NO prodrugs.
    Schönafinger K
    Farmaco; 1999 May; 54(5):316-20. PubMed ID: 10418124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinoxaline 1,4-Dioxides: Advances in Chemistry and Chemotherapeutic Drug Development.
    Buravchenko GI; Shchekotikhin AE
    Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631089
    [No Abstract]   [Full Text] [Related]  

  • 6. Regioselective Synthesis of NO-Donor (4-Nitro-1,2,3-triazolyl)furoxans via Eliminative Azide-Olefin Cycloaddition.
    Stebletsova IA; Larin AA; Ananyev IV; Fershtat LL
    Molecules; 2023 Oct; 28(19):. PubMed ID: 37836813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks.
    Scatena R; Bottoni P; Pontoglio A; Giardina B
    Curr Med Chem; 2010; 17(1):61-73. PubMed ID: 19941478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imines as acceptors and donors in N-heterocyclic carbene (NHC) organocatalysis.
    Das TK; Biju AT
    Chem Commun (Camb); 2020 Jul; 56(61):8537-8552. PubMed ID: 32602493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticulated Nitric Oxide Donors and their Biomedical Applications.
    Seabra AB; Duran N
    Mini Rev Med Chem; 2017; 17(3):216-223. PubMed ID: 27515711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Developments in Drug Design of NO-donor Hybrid Compounds.
    Sharma R; Joubert J; Malan SF
    Mini Rev Med Chem; 2018; 18(14):1175-1198. PubMed ID: 29663881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of nitric oxide donors for the treatment of cardiovascular diseases.
    Katsumi H; Nishikawa M; Hashida M
    Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):204-8. PubMed ID: 17630946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications.
    Andrabi SM; Sharma NS; Karan A; Shahriar SMS; Cordon B; Ma B; Xie J
    Adv Sci (Weinh); 2023 Oct; 10(30):e2303259. PubMed ID: 37632708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric Oxide (NO)-Releasing Macromolecules: Rational Design and Biomedical Applications.
    Cheng J; He K; Shen Z; Zhang G; Yu Y; Hu J
    Front Chem; 2019; 7():530. PubMed ID: 31403044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New NO-donors with antithrombotic activities and vasodilating activities, III: 3,4-disubstituted N-nitroso-5-sydnone imines.
    Rehse K; Schleifer KJ
    Arch Pharm (Weinheim); 1993 Dec; 326(12):929-39. PubMed ID: 8122963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-nitroso compounds: synthesis, physicochemical properties and biological activities.
    Gooden DM; Chakrapani H; Toone EJ
    Curr Top Med Chem; 2005; 5(7):687-705. PubMed ID: 16101429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced nitric oxide donors: chemical structure of NO drugs, NO nanomedicines and biomedical applications.
    Yang Y; Huang Z; Li LL
    Nanoscale; 2021 Jan; 13(2):444-459. PubMed ID: 33403376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Biological Evaluation of Novel Heterocyclic Imines Linked Coumarin- Thiazole Hybrids as Anticancer Agents.
    Goud NS; Ghouse MS; Vishnu J; Pranay J; Alvala R; Talla V; Qureshi IA; Alvala M
    Anticancer Agents Med Chem; 2019; 19(4):557-566. PubMed ID: 30734685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advancements in Polymeric
    Mondal A; Paul S; De P
    Biomacromolecules; 2024 Sep; 25(9):5592-5608. PubMed ID: 39116284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans.
    Feelisch M; Schönafinger K; Noack E
    Biochem Pharmacol; 1992 Sep; 44(6):1149-57. PubMed ID: 1358072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics Studies Suggest That Nitric Oxide Donor Furoxans Inhibit In Vitro Vascular Smooth Muscle Cell Proliferation by Nitric Oxide-Independent Mechanisms.
    Lazzarato L; Bianchi L; Andolfo A; Granata A; Lombardi M; Sinelli M; Rolando B; Carini M; Corsini A; Fruttero R; Arnaboldi L
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.